Clinical research for treatment of coronary heart disease with autologous bone marrow mesenchymal stem cell and mononucleus cell transplantation
- VernacularTitle:自体骨髓间充质干细胞和单个核细胞移植治疗冠心病的临床研究
- Author:
Fang ZHOU
;
Fumin ZHANG
;
Zhijian YANG
- Publication Type:Journal Article
- Keywords:
Bone marrow stem cell;
Coronary heart disease;
Myocardial infarction
- From:
Chinese Journal of Interventional Cardiology
2003;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of transplantation of autologous bone marrow mesenchymal stem cells (BMSCs) and mononucleus cells (BMMNCs) for treating coronary heart disease. Methods Ten patients who had suffered from coronary heart disease with myocardial infarction, were selected. In 7 patients BMSCs+BMMNCs were transplanted immediately following PCI and 3 patients only accepted transplantation of BMSCs+BMMNCs without PCI. Autologous BMSCs+BMMNCs were isolated and cultured for 2-3 weeks. And (0.9～3.5)?106 BMSCs+1.6～6.1?106 BMMNCs were transplantated through intracoroary way. Cardiac functions were determined by 2-D echocardiography、 technetium- 99m methoxyisobutylisonitrile ( 99m Tc-MIBI) and ECG Holter monitor before and 6 months after the procedure. Results Left ventricular ejection fraction (LVEF) was significantly increased by 10.5% (4.0%-18.0%) and left ventricular diastolic diameter(LVDd) reduced by 2.2 mm (-4 mm-8 mm) and neither obvious arrhythmia nor complication was observed during the 6-12 months′ follow up in all the 10 patients. Conclusion The preliminary study showed that in the patients who suffered from coronary heart disease complicated with myocardiac infarction, transplantation of BMSCs+BMMNCs could improve cardiac function and cardiac perfusion without significant complication and arrhythmia during the 6-12 months′ follow-up.
